In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)
In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)
In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim’s combination stroke prevention drug, Aggrenox. The case alleges that Boehringer paid its would-be generic competitors (Duramed, later known as Barr, and still later known as Teva) to delay launching their less-expensive generic versions of Aggrenox, in what is known as a “pay for delay” conspiracy. The case settled for $146 million in late 2017.
Details
Counsel
Joseph T. Lukens
jlukens@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Peter Kohn
pkohn@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Office
Pennsylvania
1617 JFK Boulevard, Suite 1550
Philadelphia Pennsylvania 19103
Phone (215) 277-5770
Fax (215) 277-5771
